I think this is an excellent move. What they're saying is that a major NY based investment bank has signed up with ALT for the purpose of selling or licensing both the PeriCoach and the AutoStart Burette. NY based investment banks only get paid on a success fee. Navigant must be confident of a deal otherwise they would not have signed with ALT. Navigant is one of the heavy hitters with over 5500 employees and 47 global offices.
After this announcement BioTech Daily wrote the following
"Analytica says it has selected New York investment bank Navigant Capital Advisors LLC to assist in the sale or licence off its assets.
Analytica said that Navigant would assist in the process of commercializing the intra-vaginal Pericoach pelvic floor training system for incontinence, its Autostart burette and possibly the company (BD: Jun 2, 2017).
Analytica chairman Dr Michael Monsour said it was “a credit to Analytica's management and board that the company has advanced its intellectual property to a stage where such a process can be undertaken by a leading US corporate advisor”.
Analytica chief executive officer Geoff Daly told Biotech Daily that Navigant would “help us in our strategy of a licence deal, which may or may not involve the sale of the company”.
“For the last 18 months our publicly-stated strategy has been to build the best in class, prove it works and then find a multinational partner who can take it to the world,” Mr Daly said.
Analytica was unchanged at 0.4 cents."
IMHO it's a real coup that ALT has been able to sign up a top NY investment bank like Navigant. Most small Aus companies do not get past the front door of NY investment bankers.
ALT Price at posting:
0.4¢ Sentiment: None Disclosure: Held
